SCHEMBL638360

SCHEMBL638360

O=C(O)CCC(=O)OC(=O)CCCC(=O)OCO

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.43
SLC22A6 Q4U2R8 1/20 0.40
LMNA P02545 4/20 0.39
EGLN1 Q9GZT9 2/20 0.38
KDM6B O15054 1/20 0.38
KDM5C P41229 1/20 0.38
PHF8 Q9UPP1 1/20 0.38
KDM2A Q9Y2K7 1/20 0.38
ALKBH5 Q6P6C2 1/20 0.38
SUCNR1 Q9BXA5 1/20 0.38
PAM P19021 2/20 0.37
NPC1 O15118 1/20 0.36
CAMK2A Q9UQM7 1/20 0.36
ALDH1A1 P00352 2/20 0.35
GPR84 Q9NQS5 1/20 0.33
NFKB1 P19838 1/20 0.33
PMP22 Q01453 1/20 0.33
FFAR1 O14842 1/20 0.33
FFAR4 Q5NUL3 1/20 0.33
DGKA P23743 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2177185 0.87 TSHR (0.56) TSHRSLC22A6LMNAEGLN1ALKBH5
SCHEMBL1237232 0.87 LMNA (0.50) TSHRSLC22A6LMNAEGLN1KDM6B
SCHEMBL2209527 0.87 TSHR (0.54) TSHRSLC22A6LMNAEGLN1KDM6B
SCHEMBL29212612 0.84 TSHR (0.52) TSHRSLC22A6LMNAEGLN1KDM6B
Ammonia Solution, Strong SCHEMBL28947727 0.82 TSHR (0.56) TSHRSLC22A6LMNAEGLN1KDM6B
SCHEMBL10757164 0.82 LMNA (0.55) TSHRSLC22A6LMNAPAMCAMK2A
SCHEMBL2480634 0.82 TSHR (0.56) TSHRSLC22A6LMNAEGLN1KDM6B
Adipic Acid SCHEMBL27504325 0.82 TSHR (0.56) TSHRSLC22A6LMNAEGLN1KDM6B
SCHEMBL429060 0.82 LMNA (0.53) TSHRSLC22A6LMNAEGLN1KDM6B
SCHEMBL1602470 0.82 SLC22A6 (0.61) TSHRSLC22A6LMNAEGLN1KDM6B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10689673-B2 Bioconversion process for producing nylon-7, nylon-7,7 and polyesters INVISTA NORTH AMERICA S.A.R.L. (US) 2020-06-23 US disclosed
US-10577634-B2 Bioconversion process for producing nylon-7, nylon-7,7 and polyesters INVISTA NORTH AMERICA S.A.R.L. (US) 2020-03-03 US disclosed
US-20170298396-A1 BIOCONVERSION PROCESS FOR PRODUCING NYLON-7, NYLON-7,7 AND POLYESTERS INV NYLON CHEMICALS AMERICAS, LLC 2017-10-19 US disclosed
US-9650653-B2 Bioconversion process for producing nylon-7, nylon-7,7 and polyesters INVISTA NORTH AMERICA S.A.R.L. (US) 2017-05-16 US disclosed
US-20150337275-A1 BIOCONVERSION PROCESS FOR PRODUCING NYLON-7, NYLON-7,7 AND POLYESTERS INVISTA TECHNOLOGIES S.A.R.L. (CH) 2015-11-26 US disclosed
US-20150240226-A1 NUCLEIC ACIDS AND PROTEINS AND METHODS FOR MAKING AND USING THEM BP CORP NORTH AMERICA INC (US) 2015-08-27 US disclosed
US-8962800-B2 Nucleic acids and proteins and methods for making and using them BP CORPORATION NORTH AMERICA INC. (US) 2015-02-24 US disclosed
US-20140242655-A1 Bioconversion Process for Producing Nylon-7, Nylon-7, 7 and Polyesters INVISTA TECHNOLOGIES S.A R.L. (CH) 2014-08-28 US disclosed
US-20120266329-A1 Nucleic Acids and Proteins and Methods for Making and Using Them BP CORPORATION NORTH AMERICA INC. (US) 2012-10-18 US disclosed
US-8119385-B2 Nucleic acids and proteins and methods for making and using them BP CORPORATION NORTH AMERICA INC. (US) 2012-02-21 US disclosed
US-20110296543-A1 NUCLEIC ACIDS AND PROTEINS AND METHODS FOR MAKING AND USING THEM THE UNIVERSITY OF CALIFORNIA (US) 2011-12-01 US disclosed
US-20100011456-A1 Nucleic Acids and Proteins and Methods for Making and Using Them VERENIUM CORPORATION (US) 2010-01-14 US disclosed
EP-1765418-A4 METHOD FOR ENHANCING PRODUCTION OF ISOPRENOID COMPOUNDS UNIV CALIFORNIA (US) 2008-07-02 EP disclosed
EP-1765418-A2 METHOD FOR ENHANCING PRODUCTION OF ISOPRENOID COMPOUNDS The Regents of the University of California (US) 2007-03-28 EP disclosed
WO-2006085899-A2 METHOD FOR ENHANCING PRODUCTION OF ISOPRENOID COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150240226-A1 NUCLEIC ACIDS AND PROTEINS AND METHODS FOR MAKING AND USING THEM POLN, POLM, POLI TSHR 2116/4885SLC22A6 3956/4885LMNA 389/4885
US-20120266329-A1 Nucleic Acids and Proteins and Methods for Making and Using Them POLN, POLM, POLI TSHR 2116/4885SLC22A6 3956/4885LMNA 389/4885
US-20100011456-A1 Nucleic Acids and Proteins and Methods for Making and Using Them POLN, POLM, POLI TSHR 2116/4885SLC22A6 3956/4885LMNA 389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.